Mitera Biosciences

Mitera Biosciences is a private, preclinical biotech founded in 2020 and headquartered in Bellevue, Washington (with operations in San Diego), focused on immune tolerance. The company is developing therapeutic candidates derived from a natural human placental/thymic protein, with a novel mechanism designed to simultaneously impair effector T cells, proliferate regulatory T cells, and downregulate B cell activation. With intellectual property licensed from Cedars-Sinai Medical Center and recent seed funding, Mitera is advancing its lead program toward clinical development for transplant rejection and autoimmune disorders, targeting a significant unmet need for non-toxic immunosuppression.

Therapeutic platform based on a natural human protein expressed in the placenta and thymus, believed to regulate maternal-fetal tolerance. Engineered to simultaneously impair effector T cells, proliferate regulatory T cells, and downregulate B cell activation.

Mitera operates in highly competitive fields dominated by large pharma and numerous biotechs. It faces competition from standard calcineurin inhibitors (generics), newer biologics (e.g., belatacept), and a growing pipeline of agents targeting T and B cell pathways. Its key differentiation is its novel, physiology-inspired mechanism aiming to restore immune balance rather than cause broad immunosuppression.